PRESS RELEASE. Sciety’s portfolio company PeptiSystems has secured an investment from Rubicon Healthcare Partners, making Rubicon a new shareholder in the company. The investment strengthens PeptiSystems’ position in a rapidly growing market segment and marks the next step in its international expansion.
PeptiSystems develops and sells synthesis instruments that streamline the production of active pharmaceutical ingredients for peptide- and oligonucleotide-based drugs. The company is in a strong growth phase with a growing customer base and increasing international interest. With the new investment, PeptiSystems can accelerate its global expansion and meet the growing demand for advanced pharmaceutical manufacturing with scalable and cutting-edge production solutions.
In 2024, Sciety led a SEK 45 million financing round in PeptiSystems. Over the past year, the company has taken several important steps in its commercial development – increasing sales in the United States, signing a new distribution agreement in China, establishing collaborations with leading contract manufacturers in India, and entering an exclusive global partnership with Asahi Kasei Bioprocess America (AKBA) in the field of peptide synthesis. The delivery of the synthesis instrument OligoNavigator to the pharmaceutical company Servier marks another key milestone in the company’s international expansion.
Earlier this year, the company also strengthened its board by appointing Nick Roelofs, who brings international experience from Agilent Technologies and Bio-Rad Laboratories. The appointment aligns with Sciety’s strategy as an active owner to strengthen the organisations and growth potential of its portfolio companies.
Rubicon now joins as a new investor, broadening the ownership base as PeptiSystems enters the next phase of its commercial expansion. Rubicon Healthcare Partners is an investment firm specialising in growth investments in Nordic life science companies providing products and technologies to the healthcare and biotechnology industries.
“Rubicon Healthcare Partners’ investment in PeptiSystems is a clear validation of the company’s progress and market position. As a growth equity investor focused on Nordic life science companies, Rubicon will be an important partner in PeptiSystems’ next phase, benefiting both the company and existing shareholders. For us at Sciety, the investment confirms our ability to identify companies with leading technologies, experienced teams, and strong market potential,” says Andreas Lindblom, Managing Partner at Sciety.
“This is an important investment for PeptiSystems. With Rubicon as a shareholder, we gain a strong partner who shares our ambition to scale up the technology for industrial application and establish it globally. The capital and expertise they contribute will enable us to accelerate our commercialisation and strengthen our position in the market,” says Karin Granath, CEO of PeptiSystems.
The transaction is subject to customary closing conditions, including review under Sweden’s Foreign Direct Investment screening legislation.
For more information, please contact:
Andreas Lindblom, Managing Partner, Sciety
andreas.lindblom@sciety.se | +46 70 375 73 73
Karin Granath, CEO, PeptiSystems
karin.granath@peptisystems.com | +46 702 82 07 47
About Sciety
Sciety is a long-term investment partner and investor in life science and health tech, with a focus on the Nordic region. We identify and invest in growth companies with the potential to create significant value for both investors and society, and with a clear path towards a future exit. We lead investment processes and invest alongside leading venture capital firms, family offices, and through our investor network, Sciety Venture Partners. Our goal is for growth companies within life science and digital health to scale and succeed, making scientific breakthroughs in medicine and technology accessible to people all over the world. For more information, visit www.sciety.com and follow us on LinkedIn.
About PeptiSystems AB
PeptiSystems is a life science company developing a new generation of flow-through instruments for peptide and oligonucleotide therapeutics synthesis. Utilising proprietary flow-through column technology, PeptiSystems’ instruments significantly reduce production times, enhance synthesis control, and minimise raw material consumption while maintaining high purity and yield. With scalability in mind, these next-generation synthesis instruments seamlessly adapt from small-scale development to large-scale production, enabling pharmaceutical companies and CDMOs to meet the growing global demand for high-performance, cost-effective, and sustainable manufacturing processes. PeptiSystems is headquartered in Uppsala, Sweden. For more information, please visit www.peptisystems.com and follow us on LinkedIn.
Receive news from Sciety
Sign up for our newsletter to receive news, industry insights, and updates on our investments.
Disclaimer: The information contained in our emails and communications is intended for informational purposes only and is not intended to constitute advice or recommendations on any investment. We do not guarantee the accuracy, completeness, timeliness, or suitability of any information provided. Please note that our communications are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation. In particular, our communications are not intended for persons in the United States or Australia. We do not accept any liability for any loss or damage arising from the use of our communications, including but not limited to any investment decisions made based on the information provided. Furthermore, please note that any investment in private companies involves a high degree of risk and is not suitable for all investors. Before making any investments, you must read and accept our general terms and conditions for investments, which can be found at the following link: General Terms and Conditions for Investments.
Latest news
